AnyTime News 
ANYTIME NEWS NETWORK. In a major step toward enhancing transparency and systemic risk monitoring in financial markets, the Reserve Bank of India (RBI) has issued a draft circular introducing the Unique Transaction Identifier (UTI) for all Over-the-Counter (OTC) derivative transactions in India. The new framework, set to come into effect from April 1, 2026, aims to align India’s reporting standards with global best practices and provide policymakers with a comprehensive view of OTC derivative exposures.
The concept of UTI has been globally recognized as a critical data element for derivative trade reporting. By assigning a unique code to every OTC derivative transaction, regulators will be able to track contracts throughout their lifecycle, thereby improving market surveillance and reducing systemic vulnerabilities.
Coverage Across Key Derivative Segments
The UTI requirement will apply to all OTC transactions in rupee interest rate derivatives, government securities futures, foreign exchange derivatives, foreign currency interest rate derivatives, and credit derivatives. The regulatory directions have been issued under Sections 45U and 45W of the RBI Act, 1934.
Under the draft framework, each UTI will be created in line with the February 2017 technical guidance issued by CPMI-IOSCO. The identifier will have a maximum length of 52 characters, comprising the Legal Entity Identifier (LEI) of the generating entity followed by a unique code. Importantly, the UTI will remain consistent for the entire lifecycle of a derivative contract unless a new contract is created due to lifecycle events such as novation.
Clear Waterfall Mechanism for UTI Generation
The RBI has laid out a structured “waterfall” approach for determining which entity is responsible for generating the UTI.
For transactions reportable only in India, the Central Counterparty (CCP) will generate the UTI where it acts as counterparty. If executed on an Electronic Trading Platform (ETP), the ETP will generate the identifier. If neither applies, the Clearing Corporation of India Ltd – Trade Repository (CCIL-TR) will generate it.
For cross-border transactions reportable in India and one or more foreign jurisdictions, the framework provides additional clarity. If a foreign jurisdiction has an earlier reporting timeline, the entity specified under that jurisdiction’s requirements will generate the UTI. Where no such earlier timeline exists, counterparties must mutually agree on the generating entity; failing that, CCIL-TR will step in.
If a UTI cannot be reported within the prescribed timeline due to cross-border constraints, market participants may submit it within two business days of the trade date. Any UTI generated earlier by CCIL-TR in such cases will be treated as interim.
No Change in Existing Reporting Obligations
The RBI has clarified that the introduction of UTI will not alter the scope of existing mandatory reporting requirements for OTC derivative contracts. Market participants must continue reporting trades to CCIL-TR as per prevailing norms. Revised reporting formats and operational guidelines will be issued separately to incorporate UTI reporting standards.
The central bank has emphasized that all eligible market participants must put in place necessary systems and compliance mechanisms well before the April 2026 implementation date.
With this move, the RBI aims to enhance transparency, strengthen risk assessment capabilities, and harmonize India’s derivative market infrastructure with international regulatory standards.
